Quantitative PSMA positron emission tomography (PET) analysis has shown high performance in identifying clinically significant intraprostatic lesions and in providing noninvasive and objective risk stratification of patients with primary PCa [85,86,87,88,89,90,91,92,93,94,95]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.